Phase II Study of Sintilimab, a PD-1 Inhibitor, as Second-line Treatment in FH-deficient Renal Cell Carcinoma
Overview
- Phase
- Phase 2
- Intervention
- Sintilimab
- Conditions
- Renal Cell Carcinoma
- Sponsor
- West China Hospital
- Enrollment
- 37
- Primary Endpoint
- 6-month PFS rate (6 month progression-free survival rate)
- Last Updated
- 5 years ago
Overview
Brief Summary
This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of Sintilimab, a PD-1 Inhibitor, as Second-line Treatment in FH-deficient Renal Cell Carcinoma.
Detailed Description
Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare subtype of RCC characterized by germline/somatic mutation of the fumarate hydratase (FH) gene, and is an extremely aggressive tumor, with a propensity to disseminate early even in the setting of a small primary tumor. Loss-of-function mutation of FH results in the accumulation of fumarate, impairment of oxidative phosphorylation, alteration of the metabolic state, and stabilization of hypoxia-inducible factor (HIF)-1α, thus activating angiogenic and oxidative stress response pathways. Unlike the robust response of clear cell RCC (ccRCC) to antiangiogenic agents, blocking the antiangiogenic pathway does not lead to better outcomes in FH-deficient RCC. Anti-mTOR agents are also ineffective. Although the National Comprehensive Cancer Network (NCCN) guideline recommends the combination of bevacizumab plus erlotinib or everolimus for metastatic FH-deficient RCC, high-level evidence for standardized systematic therapy remains scarce. In the present study, the investigators plan to assess the efficacy and safety of immunotherapy with Sintilimab as second-line treatment in FH-deficient RCC, and to explore potential biomarkers related to the treatment efficacy by means of detection, including but not limited to the next-generation sequencing, flow cytometry, etc.
Investigators
Hao Zeng
Professor, Doctor
West China Hospital
Eligibility Criteria
Inclusion Criteria
- •≥18 years old;
- •histopathological evidence of FH-deficient renal cell carcinoma, which was confirmed by Sanger or next-generation sequencing after initial screening by IHC.
- •included patients must be diagnosed with metastatic renal cell carcinoma or have a TNM stage IV (according to 2009 TNM Classification). Patients must have received treatment of targeted agents or immunotherapy (including cytokine therapy) before enrollment.
- •ECOG score ≤2;
- •life expectancy ≥ 3 months;
- •sign informed consent, and be able to follow the visit and related procedures stipulated in the program;
- •agree to collect tumor tissue, blood and other specimens required by this study and apply them to relevant studies;
- •important organs and bone marrow functions meet the following requirements: absolute neutrophil count (ANC) ≥1.5×109/L, platelet (PLT) ≥100×109/L, hemoglobin (HGB) ≥9g/dL;Liver function: serum total bilirubin (TBIL) ≤1.5 times normal upper limit (ULN), alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤2.5 times ULN, serum albumin (ALB) ≥ 2.8g /dL. Renal function: serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥40 mL/min
Exclusion Criteria
- •patients with other malignant tumors with different primary sites or histology from the tumor evaluated in this study within 2 years of personal history, except those with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or cervical carcinoma in situ under good control;
- •major surgery or severe trauma within 4 weeks before enrollment;
- •immunosuppressive drugs were used within 4 weeks prior to the first dose of study therapy, excluding local glucocorticoids, inhaled or otherwise, or systemic glucocorticoids at physiological doses (i.e., no more than 10mg/ d prednisone or equivalent doses of other glucocorticoids);
- •known or suspected active autoimmune diseases (congenital or acquired), such as interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, thyroiditis, etc. Patients with type 1 diabetes with good insulin control can also be enrolled.
- •known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
- •allergic to any component of monoclonal antibody;
- •suffering from other uncontrolled serious diseases, including but not limited to: A) severe infection in the active phase or clinically poorly controlled; B) HIV infection (HIV antibody positive); C) acute or chronic active hepatitis b (HBsAg positive and HBV DNA\>1\*103/ml) or acute or chronic active hepatitis c (HCV antibody positive and HCV RNA\>15IU/ml); D) active tuberculosis, etc.;
- •class iii-iv congestive heart failure (New York heart association classification), poorly controlled and clinically significant arrhythmia;
- •uncontrolled arterial hypertension (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥100mmHg);
- •had any arterial thrombosis, embolism or ischemia, such as myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, etc. within 6 months before the selected treatment;
Arms & Interventions
Sintilimab
Sintilimab is administered in this arm.
Intervention: Sintilimab
Outcomes
Primary Outcomes
6-month PFS rate (6 month progression-free survival rate)
Time Frame: Up to 24 months
Disease progression was defined as the time from first administration of Sintilimab to progression of disease (PD) or death, according to the Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST).
Secondary Outcomes
- Progression-free survival (PFS)(Up to 24 months)
- Overall survival (OS)(Up to 24 months)
- Visual analogue scale (VAS)(Up to 24 months)
- Objective response rate (ORR)(Up to 24 months)
- Duration of response (DOR)(Up to 24 months)
- Functional Assessment of Cancer Therapy- Kidney Symptom Index- Disease related Symptoms (FKSI-DRS)(Up to 24 months)
- Functional Assessment of Cancer Therapy (FACT)-Kidney Symptom Index 19 (FKSI-19)(Up to 24 months)
- EuroQol five-dimension scale (EQ-5D)(Up to 24 months)
- Frequency of treatment-related adverse events (AEs)(Up to 24 months)